DELTA-FLY PHARMA, INC.

Other languages Delta-Fly Pharma, Inc.

Equities

4598

JP3549370009

Market Closed - Japan Exchange Other stock markets 11:30:00 02/05/2024 am IST			5-day change	1st Jan Change
739 ^JPY	+1.23%		-5.01%	-27.19%

08/04	Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	CI
11/03	Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Delta-Fly Pharma Inc.: Mitteilung der Zulassung der Phase I/II-Studie zu DFP-10917 in Kombination mit Venetoclax	08/04
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	08/04
Delta-Fly Pharma Inc.: FDA-Einreichung des Protokolls der Phase I/II-Studie von DFP-10917 in Kombination mit Venetoclax (VTX) bei AML-Patienten, die mit VTX vorbehandelt wurden, umfasste ein Regime	11/03
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	11/03
Delta-Fly Pharma Inc.: Einreichung von Abstracts für klinische Phase I-Studie von DFP-14927 für die ASCO-Jahresversammlung 2024	07/02
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	07/02
Delta-Fly Pharma Inc.: Bekanntmachung des Beginns einer klinischen Phase-III-Vergleichsstudie mit DFP-14323	02/02
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	02/02
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	30/01
Delta-Fly Pharma Inc.: Aktueller Stand der Forschung und Entwicklung von DFP-10917 und DFP-14927, einem neuartigen PEG-Wirkstoffkonjugat für Patienten mit R/R AML	06/01
Delta-Fly Pharma Inc.: Zeitplan für die Zwischenanalyse der Phase-3-Studie von DFP-10917 bei rezidivierter/refraktärer akuter myeloischer Leukämie (R/R AML)	30/23/30
Delta-Fly Pharma, Inc. erhält von der US Food and Drug Administration die Orphan Drug Designation für DFP-10917	07/22/07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW